key: cord-0327068-zvak2ats
authors: Li, Zhizhen; Wu, Jianping; Zhou, Ji; Yuan, Baoshi; Chen, Jiqiao; Wu, Wanchen; Mo, Lian; Qu, Zhipeng; Zhou, Fei; Dong, Yingying; Huang, Kai; Liu, Zhiwei; Wang, Tao; Symmes, Deebie; Gu, Jingliang; Sho, Eiketsu; Zhang, Jingping; Chen, Ruihuan; Xu, Ying
title: A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases
date: 2021-08-27
journal: bioRxiv
DOI: 10.1101/2021.08.26.457884
sha: adfaed0d5731dc264148030e288e402e7a6e8af5
doc_id: 327068
cord_uid: zvak2ats

Damage in COVID-19 results from both the SARS-CoV-2 virus and its triggered overreactive host immune responses. Therapeutic agents that focus solely on reducing viral load or hyperinflammation fail to provide satisfying outcomes in all cases. Although viral and cellular factors have been extensively profiled to identify potential anti-COVID targets, new drugs with significant efficacy remain to be developed. Here, we report the potent preclinical efficacy of ALD-R491, a vimentin-targeting small molecule compound, in treating COVID-19 through its host-directed antiviral and anti-inflammatory actions. We found that by altering the physical properties of vimentin filaments, ALD-491 affected general cellular processes as well as specific cellular functions relevant to SARS-CoV-2 infection. Specifically, ALD-R491 reduced endocytosis, endosomal trafficking, and exosomal release, thus impeding the entry and egress of the virus; increased the microcidal capacity of macrophages, thus facilitating the pathogen clearance; and enhanced the activity of regulatory T cells, therefore suppressing the overreactive immune responses. In cultured cells, ALD-R491 potently inhibited the SARS-CoV-2 spike protein and human ACE2-mediated pseudoviral infection. In aged mice with ongoing, productive SARS-CoV-2 infection, ALD-R491 reduced disease symptoms as well as lung damage. In rats, ALD-R491 also reduced bleomycin-induced lung injury and fibrosis. Our results indicate a unique mechanism and significant therapeutic potential for ALD-R491 against COVID-19. We anticipate that ALD-R491, an oral, fast-acting, and non-toxic agent targeting the cellular protein with multipart actions, will be convenient, safe, and broadly effective, regardless of viral mutations, for patients with early- or late-stage disease, post-COVID complications and other related diseases. IMPORTANCE With the Delta variant currently fueling a resurgence of new infections in the fully-vaccinated population, developing an effective therapeutic drug is especially critical and urgent in fighting COVID-19. In contrast to the many efforts to repurpose existing drugs or address only one aspect of COVID-19, we are developing a novel agent with first-in-class mechanism-of-actions that address both the viral infection and the overactive immune system in the pathogenesis of the disease. Unlike virus-directed therapeutics that may lose efficacy due to viral mutations and immunosuppressants that require ideal timing to be effective, this agent, with its unique host-directed antiviral and anti-inflammatory actions, can work against all variants of the virus, be effective during all stages of the disease, and even resolve post-disease damage and complications. A further development of the compound will provide an important tool in the fight against COVID-19, its complications, as well as future outbreaks of new viruses.

Vaccines against SARS-CoV-2 have been rapidly developed and rolled out to 75 contain the COVID-19 pandemic, however the infection-blocking immunity induced by 76 vaccination has been shown to wane quickly, even though disease-reducing immunity 77 may be long-lived (1). Vaccination primarily generates IgG antibodies that circulate in 78 the blood, not IgA antibodies in the mucosa of the respiratory tract which are a critical 79 component of the mucosal immunity that prevents SARS-CoV-2 from initiating its 80 infection (2, 3). The spike mRNA-based vaccination induces strong, persistent antibody 81 responses but accompanied by a limited or absent T-cell response (4, 5) . In addition, 82 the virus has now demonstrated an ability to rapidly mutate during its transmission and 83 to generate mutants that not only provide enhanced infectivity, but also an acquired 84 ability to escape from therapeutic antibodies and those induced by infection or 85 vaccination. Several Variants of Concern (VOCs) have emerged within a short period of 86 time, especially the Delta variant (6, 7) that is currently fueling a resurgence of new 87 5 infection in fully vaccinated population. This virus appears to present a persistent 88 problem despite vaccines, and therefore effective therapeutics are critically needed. 89

To date, most therapeutic interventions have been focused either on stopping 90 viral infection or reducing virus-induced hyper-inflammation. Antiviral approaches can 91 be virus-directed or host-directed. Virus-directed approaches include blocking viral entry, 92 preventing maturation of viral proteins, and disrupting the viral RNA-synthesis 93 machinery. All face challenges from the rapid viral mutations that could make them 94 ineffective over time. In addition, these types of agents must be given early during an 95 infection to be effective, as viral load has been shown to peak on or before symptom 96 onset (8) with very few infectious viruses present in the upper respiratory tract 10 days 97 after the onset of symptoms, even without treatment (9). A delayed or longer anti-viral 98 treatment in the course of COVID-19 has been shown to lead a worse outcome (10), 99 because it is the overactivated host immune system, not the virus itself, that is driving 100 the progression and the development of serious complications. However, 101

immunomodulators have shown minimal effects and corticosteroids, moderate effects 102 only if given at the right timing, otherwise worsening the disease. Host-directed antiviral 103 approaches have attracted attention because targeting host proteins offers broad-104 spectrum anti-viral actions that are hard for virus to evade through mutation. The host 105 proteins that interact with SARS-CoV-2 have been extensively profiled and a large 106 quantity of existing compounds have been screened for potential antiviral activities (11-107 15) . So far, however, no repurposed antiviral drugs addressing these host factors have 108 shown significant efficacy in clinical trials(16).

An ideal anti-COVID agent would be able to both eliminate the virus and restore 110 balance to the immune system. Several existing drugs, such as hydroxychloroquine, 111 colchicine, and ivermectin that exhibit some degree of synergistic antiviral and anti-112 inflammatory actions, have been repurposed to treat COVID-19, however, the results 113 have been controversial or inconclusive. Whether applied in early disease to prevent 114 progression, or in late stage to reduce morbidity and mortality, therapeutics with new 115 mechanisms are urgently needed to tackle the multifaceted and inter-related nature of 116 pathogenesis in SARS-CoV2 infection. 117

Vimentin, an evolutionarily very conserved intermediate filament protein with 118 diverse functions in health and disease (17), has been proposed as a host-directed 119 therapeutic target for 19) . Vimentin facilitates viral infection by serving 120 as a co-receptor and a component of the cellular transportation machinery for viral entry, 121 trafficking and egress (20). Vimentin is also specifically involved in inflammatory 122 responses, where it forms a superstructure inside regulatory T cells that mechanically 123 regulate the switch of the cells between active and inactive status (21), and provides a 124 scaffold structure that enables the NLRP3 inflammasome to assemble, activate, and 125 contribute to inflammation and lung injury (22). Targeting vimentin is unlikely to 126 generate mechanism-based toxicities because the protein has been widely recognized 127 to be non-essential from embryonic development to adulthood after the first work in 128 early 1990s demonstrated that mice lacking vimentin developed and reproduced without 129 an obvious phenotype (23). 130

We synthesized a series of small molecule compounds that can bind to vimentin 131 (24). The lead compound ALD-R491 has shown many favorable safety features: it is 132 9 however neither of cellular processes was completely blocked by the compound, with 175 endosomal trafficking impacted more than endocytosis. 176

Exosomes originate from the endocytic pathway and are released via the fusion 177 of a multivesicular body (MVB) with cell membrane (26). Using a reporter system as 178 well as a classic exosome purification method, we found that ALD-R491 inhibited 179 exosome release from Huh7 cells in a dose dependent manner (Fig. 1F) . Like the 180 effects observed on endocytosis and endosomal trafficking, the maximal rates of 181 inhibition on exosome release were plateaued at around 50% of non-drug levels. These 34.7 and 64.9 nM for the infections at MOI of 0.5, 5 and 50, respectively (Fig. 2D-E) . 220

Clearly, ALD-R491 was highly selective (> 154 at MOI of 50) and potent at blocking the 221 spike protein-ACE2-mediated viral entry, the first step of SARS-CoV2 infection. Unlike 222 virus-directed approaches aimed at blocking the binding of the spike protein with ACE2 223 receptor, which include anti-spike protein antibodies that may become futile as the 224 epitope of spike protein continues to mutate, our host-directed approach blocks the 225 cellular process that is used by the virus. As long as endocytosis remains the route for 226 their cellular entry, the compound would be equally effective for all variants. At the early stages of an infection, the innate immune system, in particular macrophage 249 M1, is as the first line of defense that prevents pathogens that have entered the tissues 250 from further dissemination. In addition to triggering an immune response and producing 251 proinflammatory cytokines, macrophages effectively phagocytose these pathogens, 252 directly destroying them inside the phagosome or lysosome. SARS-CoV2 can interrupt 253 phagolysosome function and even hijack the phagolysosome to egress from infected 254 cells (27). The SARS-CoV-2 virus has been found alive inside monocytes and 255 macrophages (28, 29), suggesting an impaired function of these cells for pathogen 256 clearance, and a problematic reservoir site that supports lingering infection. The key 257 actor for macrophage microbicidal activity is NADPH oxidase in the phagosomes which 258 produces reactive oxygen species (ROS). NADPH oxidase is a membrane-associated 259 enzyme consisting of multiple subunits. Vimentin is known to bind with p47Phox, a 260 subunit of NADPH oxidase. The association with vimentin makes the p47phox subunit 261 separated from the enzyme complex of NADPH oxidase, restraining the enzyme activity 262 thereby limiting ROS production and consequently reducing the pathogen-killing 263 efficiency of cells (30). In the mouse peritoneal macrophages, we found that p47Phox 264 13 was abundantly present in the cell periphery next to the cell membrane and colocalized 265 with vimentin. The vimentin-binding action of ALD-R491 caused a dissociation of 266 vimentin from p47Phox thereby increased the presence of p47Phox in the cytosol (Fig. 267 3A-B, Fig. S3 ), increased the production of ROS (Fig. 3C) and reduced the number of 268

Salmonella survived in the macrophages by about 30% (Fig. 3D) . These results 269 suggest a potential of ALD-R491 to increase the pathogen-killing capacity of 

In cases where the innate immunity fails to clear the pathogen, the adaptive 289 immunity is then mobilized against the infection. Although this will help control infection, to repair epithelial damage, and other tissue damage throughout the body. In severe 296 COVID-19 patients, the levels of peripheral Tregs were found to be remarkably reduced 297 (31-34), which has led to a call for Treg cell-based therapy (35) and clinical trial 298 (NCT04468971) of infusions of Treg cells. Vimentin has been previously identified as 299 forming the 'mechanical' restraint structure inside regulatory T cells that regulate their 300 switch between active and inactive status. Specifically, inside Tregs, the asymmetric 301 partitioning of vimentin forms the distal pole complex (DPC), keeping the 302 immunosuppressive molecules away from the immunological synapse that gets formed 303 between Tregs and antigen-presenting cells, thereby restraining the function of Treg 304 cells ( Fig. S3B ) (21). We hypothesized that ALD-R491 would interrupt the DPC's 305 structural integrity and directly activate Tregs to increase their dampening and balancing 306 actions, thereby addressing and potentially solving the cytokine storm of COVID. In 307 cultured mouse Treg cells treated with ALD-R491 for a short period of time (2 h), 308 concentrations as low as 0.01 M resulted in a significantly decreased proportion of 309 inactive Treg cells that had intact DPC ( Fig. 4A-B) . When disassembled, DPC would 310 release the immunosuppressive molecules, activating Treg cells. Indeed, Treg 311 suppression assay in vitro showed an increased Treg activity in the presence of ALD-312 R491 at a low concentration of 0.1 µM (Fig. 4C, Fig. S4 ). These results indicated that 313 the highly ordered DPC structure was very sensitive to ALD-R491 and Treg cells 314 lung tissue at levels sufficient to be effective, we first measured the distribution of ALD-332 R491 in tissues after oral administration. In rats gavaged with ALD-R491 at 30 mg/kg, 333 the compound was rapidly distributed in various tissues, with the highest exposure in 334 the gastrointestinal tissues as expected, enriched exposures in other tissues including 335 the lung and lymph nodes, and minimal exposure in the blood (Fig. 5A) . The compound 336 concentrations in the lung tissue 6 h after oral dosing maintained at levels as high as 337 1M, which was a concentration more than sufficient for efficacy based on its effective 338 concentrations in vitro (< 0.1M in multiple assays). These data provided the rationale 339 for dose selection and supported a daily dosing treatment regimen. 340

Next, we tested the compound in a mouse-adapted SARS-CoV-2 MA model, in 341 which the mutated SARS-CoV-2 virus can replicate in the upper and lower airways of 342 both young adult and aged BALB/c mice. The model generates more severe disease in 343 aged mice, reproducing the age-related increase in disease severity observed in 344 humans (36). In this study, we utilized aged mice (11 to 12 months) to best mimic the 345 most severe viral infection in the most vulnerable population in humans. The compound 346 was orally administered prophylactically and therapeutically. 347

Prophylactic treatment had no effects under the study execution ( Fig. S5A-F) , 348 however therapeutic treatment showed significant efficacy in multiple measurements. 349

Under the therapeutic protocol, the aged mice were administered the compound orally 350 one day after the SARS-CoV2 infection for 3 of the 5 study days on D1, D2 and D4 and 351 then sacrificed on D5. Therapeutic effects were observed more prominently in the 352 medium dose group of 10 mg/kg, as evidenced by reduced body weight loss over the 353 course of the experiment (Fig. 5B) , lower lung congestion as assessed macroscopically 354 at the necropsy (Fig. 5C) , milder lung tissue injury (Fig. 5D ) and less diffuse alveolar 355 damage (Fig. 5E ) as evaluated microscopically in the histological examination. The lung 356 tissues from mice in both the 10 and 30 mg/kg groups showed less inflammation and 357 better-preserved alveolar structures (Fig. 5F) . The viral loads in the lung tissues at the 358 end of the study at D5 were at low levels with no difference among groups (Fig. S5F) . 359

The low viral titers at D5 were expected because in this model without treatment, the 360 viral loads in the lung were shown to peak at D2 and to decrease significantly by D4 361 (36). The viral titer at D5 in this study therefore was less meaningful in terms of antiviral 362 efficacy since the virus in the surviving mice had been largely cleared regardless of 363 treatment. The therapeutic efficacy seen in vivo, particularly given that only 3 doses 364 were able to be administered relative to a 5-day course due to site constraints during 365 the pandemic, was very significant both in its endpoints and in its short treatment 366 regimen started after productive viral infection. With its dual actions of host-directed 367 antiviral and antiinflammation, ALD-R491 represents a unique promising oral agent that 368 is worth further investigation as a therapeutic against COVID. We tested the vimentin binding compound ALD-R491 in rats with bleomycin-408 induced lung fibrosis models, using prophylactic as well as therapeutic protocols. In 409 both protocols, ALD-R491 significantly ameliorated lung tissue injury and lung fibrosis. 410

Bleomycin directly injected via intra-trachea into to the unilateral lung caused massive 411 lung injury and severe lung fibrosis. Compared with the positive control treatment with 412 BIBF1120 (Nintedanib), a multiple tyrosine kinase inhibitor marketed as a first line 413 treatment for lung fibrosis, the treatment with ALD-R491 showed significantly improved 414 body weight (Fig. 6A) , indicating a superior safety profile of ALD-R491. Both therapeutic 415 and prophylactic treatment using ALD-R491 reduced bronchial and arteriole injury in the 416 fibrotic core (Fig. 6B, 6D ) and the fibrotic border (Fig. 6E, Fig. S6A ), reduced damage 417 and fibrosis in alveoli (Fig. S6B, Fig. 6C, 6F) . Interestingly, careful examination 418 revealed that the Masson's trichrome images for samples with comparable Ashcroft 419 scores exhibited a remarkable difference in connective tissue staining between 420 20 BIBF1120 and ALD-R491 groups, i.e., ALD-R491 group had a much less intense blue 421 color (stains for fibrosis) than the BIBF1120 group had (Fig. 6C) . This result indicates 422 that, when assigned comparable Ashcroft scores, the lung tissues from ALD-R491-423 treated animals had less fibers than the lung tissues from BIBF1120-treated animals, so 424 the Ashcroft scoring on lung fibrosis for ALD-R491 failed to capture this improvement in 425 visible histopathology (less blue) because it falls outside the density rubric of the 426

Ashcroft scoring matrix (scores only density, not color). This discrepancy was further 427 confirmed by collagen-I IHC staining, which showed the actual reduction in fibrosis 428 measured by collagen-I deposition was more significant than that by Ashcroft score in 429 the lung of mice treated by ALD-R491. Compared with vehicle control, both ALD-R491 430 and BIBF1120 reduced collagen-I deposition in the lung fibrosis core, with the reduction 431 of collagen more significant in ALD-R491 group than in BIBF1120 group (Fig. 6G, Fig.  432   S6C) . This was consistent with the markable difference in amounts of fibers (blue color) 433 seen by Masson's staining but not reflected by Ashcroft scores (Fig. 6C) . Although 434

Ashcroft scoring underestimated the efficacy of ALD-R491 in reducing fibrosis, the 435 results from all the evaluation criteria indicate that ALD-R491 has a superior safety 436 profile and a therapeutic potential not only in ameliorating lung injury but also in 437 preventing and treating lung fibrosis, all of which is directly relevant to use in COVID-19 438 and its complications. binding to vimentin (Fig. 7) . This first-in-class mechanism of action is fundamentally 462 different from that of any existing pipeline agent, or any repurposed drug (13, 42) . 463 Importantly, the antiviral mechanisms of ALD-R491 create multiple novel actions against 464 viral infection: first, a blockade of spike protein and ACE2-mediated endocytosis and of 465 endosomal trafficking and exosomal release, which are the cellular processes that are 466 unlikely to be evaded by the virus even with mutations; and second, an enhanced ability 467 of macrophages to kill pathogens, which is critical both for containing the viral spread at 468 early stages and for clearing persistent viral presence after the acute phase of infection. 469

The anti-inflammatory mechanisms of ALD-R491 could also create multiple actions that 470 are novel and different from existing agents, and highly sought for their specific potential 471 against the hyperinflammation of COVID-19: a direct Treg activation, as shown in this 472 study; and a potential inhibition on NLRP3 inflammasome activation, as previous study 473

suggested [22] . The therapeutic effects of the compound on the aged mice with a full-474 blown, ongoing SARS-CoV2 infections is not only a proxy for its efficacy against severe 475 disease, but also informs its use in the elderly and fragile, two groups of COVID-19 476 patients with the most concerning unmet need. The therapeutic and preventive effects 477 of the compound on lung injury and fibrosis make it also applicable to patients with post-478 COVID complications. With oral administration, ALD-R491can be conveniently dosed 479 and broadly accessible to non-hospitalized patients , a population that is growing rapidly 480 as this first pandemic matures. The binding of ALD-R491 to vimentin altered the organization and dynamism of 501 the filaments (Fig. 1A, 1B) , which impacted multiple cellular processes in the cells (Fig. 502 1D-F), leading to a blockade of the initial steps of SARS-CoV-2. Vimentin can function 503 as an attachment receptor on the cell surface and assist membrane and vesicle 504 transport at both anterograde and retrograde directions inside the cell (45, 46) . It 505 appears to be widely hijacked by viruses for facilitating their infection, as seen with both 506 SARS-CoV (47) and SARS-CoV2 (48). Our study showed that ALD-R491 potently 507

inhibited Spike protein-ACE2 mediated viral entry through a blockade of endocytosis, 508 the first step of the viral infection (Fig. 2) . It has been demonstrated that newly 509 assembled SARS-CoV2 particles in the host cell, rather than budding to exit, egress 510 from the cells by fusing multiple vesicle body (MVB)-like structure with the cell 511 membrane, resembling exosomal or lysosomal release pathways (27, 49) . Our study 512

showed that vimentin regulated exosomal pathways (25) and that ALD-R491 dose-513 dependently inhibited exosome release (Fig. 1F) , which could lead to a blockade of the 514 viral egress. All these actions contribute to a multi-part host-directed antiviral 515 mechanism that offers a multi-part blockage of the transportation machinery hijacked by 516 viruses for productive infection. As the compound acts on cellular processes not the 517 virus itself, it therefore applies to all the SARS viruses regardless of strains or mutations, 518 which is especially advantageous because of the rapid evolution of current SARS-CoV-519 2 and the potential for future outbreak of other coronaviruses. The S1 protein of SARS-CoV-2 has been found persistently present in CD16+ 531 monocytes of post-COVID patients for more than a year (50), suggesting the failure of 532 monocytes to clear the virus. It remains to be investigated whether monocytes and 533 macrophages can support active replication of SARS-CoV2, as has been reported for 534

Regardless, monocytes and macrophages may still serve as a permissive system 536 and/or as a viral reservoir, both of which are known to enable virus to spread to other 537 tissues or anchor specifically within the pulmonary parenchyma (51-53), especially 538 when there is a long duration between the onset of symptoms and the development of 539 respiratory failure (6-12 days), or a prolonged course (several months or longer) of 540 syndromes in COVID long-haulers (54). Compromised ability of monocytes and 541 macrophages to clear pathogens in COVID patients might lead to the persistence of the 542 virus inside the cells, escalating a proinflammatory response during the acute phase, 543

and recurring injuries and lingering symptoms in the post-acute phase. Enhancing the 544 ability of macrophages to clear pathogens (Fig. 3A-B, Fig. S3) , ALD-R491 could 545 therefore be one of ALD-R491's most distinct, significant, and unique therapeutic 546 benefits in patients with COVID as well as with post-COVID syndromes. 547

Direct Treg activation a unique feature of ALD-R491 (Fig. 4, Fig. S4 ). The 548 binding of ALD-R491 to vimentin physically disassembles DPC, therefore, directly 549 activates Tregs. This activation occurs rapidly (less than 2 h), unlike other Treg 550 activating mechanisms that require changes in signaling pathway or gene expression, 551

which are indirect and slow acting in nature. For COVID-19 with its rapid disease 552 progression, prompt intervention appears to be especially important, which makes the 553 fast-acting ALD-R491 advantageous. In addition, Treg activation via vimentin targeting 554 was shown not to alter homeostasis of Tregs (55) and therefore would not cause 555 general immunosuppression, which makes it fundamentally different from the use of 556 steroids. Separated from its immune-related functions, Treg activation has been shown 557 to have a major direct and non-redundant role in tissue repair and maintenance (56). 558

Through directly activating Tregs and other mechanisms, ALD-R491 could not only 559 dampen the overactive immune system without compromising its antiviral response, but 560 also prevent tissues from damage and facilitate their repair. Reduced tissue injury by 561 ALD-R491 has been consistently observed in our studies across different animal 562 models (Fig. 5-6) . 563

Anti-fibrosis activity of ALD-R491 is a further additive to a complete view of its 564 impact on COVID-19. Lung pathologies from COVID-19 patients and computed 565 tomography scans of the chest in post-COVID-19 patients showed a significant increase 566 in fibrosis score (44). Fibroblasts are the primary mesenchymal cells in lung tissues. 567

Overactivation of fibroblasts is the direct cause of lung fibrosis. Alveolar fibroblasts in 568 acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) exhibit a 569 persistent activated phenotype with enhanced migratory and collagen-1 production 570 capacities. Vimentin is the major intermediate filament protein in fibroblasts, promoting 571 the motility and invasiveness of cell and the production of collagen [40] . Targeting 572 vimentin has been shown effective in reducing lung fibrosis (22, 41). As lung fibrosis 573 can develop and persist in patients that have recovered from severe COVID-19 (57), the 574 antifibrotic activity of ALD-R491 (Fig. 6) should provide additional values against 575

In summary, the vimentin binding compound ALD-R491 impacts multiple cellular 577 processes as well as various types of cells that are involved in the pathogenesis of 578 COVID-19. Its multi-part host-directed antiviral and anti-inflammatory actions and its 579 broad preclinical efficacy and make the compound a promising drug candidate worth 580 further development and exploration for the treatment of COVID-19 and other related 581 diseases. 582 583 584

The compound 586

The vimentin-binding compound used in this study was ALD-R491, (E) -1 -(4 -587 fluorophenyl) -3 -(4 -(4 -(morpholine -1 -yl) -6 -styryl -1, 3, 5 -triazinyl -2 -amino) 588 phenyl) urea. It has a molecular formula of C28H26FN7O2 and a purity of > 98%. The Briefly, single-cell suspension from mouse spleen were incubated with anti-CD4-biotin 692 antibody (Biolegend, 100508) then streptavidin-microBeads (Miltenyi, . grade) maintained at a temperature of 20 to 26 °C and a relative humidity of 40% to 725 70%. Fluorescent lighting was provided illumination approximately a 12-hr light/dark 726 cycle per day. Total of 18 rats (9/gender) were used in the study. Only data from 9 727 female animals (3 animals per time point) are presented. 728 Experiment procedures, data acquisition and analysis: The 9 female rats in 3 729 groups with body weights from 195 to 214 g were orally administered ALD-R491 at 30 730 mg/10 ml/kg. At 1, 2, and 6 h after drug administration, one group of the animals were 731 anesthetized and then euthanized using abdominal aorta exsanguinations, and their 732 blood and tissue samples were taken. The concentrations of ALD-R491 in rat plasma, 733 tissue, feces, urine, and bile samples were analyzed by the validated LC-MS/MS 734 methods with the LLOQ (Lower Limit of Quantification) concentrations of 0.500 ng/mL 735 for plasma, 0.500 ng/mL (equal to 25.0 ng/g after conversion) for tissue. The 736 concentration value below LLOQ was set as 0 for the purpose of calculation. Software 737 of LabSolutions (Version 6.81 SP1) from SHIMADZU Company was used for outputting 738 raw chromatograms and generating concentration and accuracy results of the plasma 739 samples. WinNonlin was used for distribution data statistical analysis (including mean, 740

Immunological characteristics govern 920 the transition of COVID-19 to endemicity

COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection

Mucosal immunity to severe acute 925 respiratory syndrome coronavirus 2 infection

SARS-CoV-2 mRNA vaccines induce persistent human 930 germinal centre responses

SARS-CoV-2 infection rescues B and T cell responses to variants after first 936 vaccine dose

SARS-CoV-2 variant B.1.617 is 940 resistant to bamlanivimab and evades antibodies induced by infection and 941 vaccination

Reduced sensitivity of SARS-CoV-2 947 variant Delta to antibody neutralization

Temporal dynamics in viral 951 shedding and transmissibility of COVID-19

Virological assessment of hospitalized patients with COVID-2019

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

The Global Phosphorylation Landscape of 971 SARS-CoV-2 Infection

Comparative host-coronavirus protein 980 interaction networks reveal pan-viral disease mechanisms

A SARS-CoV-2 protein interaction map 990 reveals targets for drug repurposing

SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Puschnik 1003 AS. 2021. Genetic Screens Identify Host Factors for SARS-CoV-2 and Common 1004

WHO Solidarity Trial Consortium

Repurposed Antiviral Drugs for 1014

Covid-19 -Interim WHO Solidarity Trial Results

Vimentin Diversity in Health and Disease

Vimentin as a target for the 1018 treatment of COVID-19

Multifaceted Player and Potential Therapeutic Target in Viral Infections

The diverse roles and 1023 dynamic rearrangement of vimentin during viral infection

The vimentin intermediate filament network restrains regulatory 1030

T cell suppression of graft-versus-host disease

the NLRP3 inflammasome

Mice lacking vimentin develop and reproduce without an obvious phenotype

SARs of a novel series of s-triazine compounds targeting vimentin to 1040 induce methuotic phenotype

A Small Vimentin-Binding Molecule Blocks Cancer 1043

Exosome Release and Reduces Cancer Cell Mobility

The biology, function, and biomedical applications of 1046 exosomes

Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway

macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis

Circuits between infected macrophages and T cells in 1063 SARS-CoV-2 pneumonia

Murine colitis is 1067 mediated by vimentin

Dysregulation of Immune Response in Patients With Coronavirus

Th17 and Treg cells function in 1074

SARS-CoV2 patients compared with healthy controls

The role of

CD4(+)FoxP3(+) regulatory T cells in the immunopathogenesis of COVID-19: 1078 implications for treatment

Toward an understanding of regulatory T cells in 1080 COVID-19: A systematic review

Potential of regulatory T-cell-based therapies in the management of severe 1083 COVID-19

A 1087 mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus 1093

Disease 2019 Pneumonia in Wuhan, China

Pulmonary fibrosis and COVID-19: the 1095 potential role for antifibrotic therapy

Citrullinated vimentin mediates 1099 development and progression of lung fibrosis

A novel role of vimentin filaments: binding and 1101 stabilization of collagen mRNAs

Vimentin intermediate filament 1104 assembly regulates fibroblast invasion in fibrogenic lung injury

Drug 1107 repurposing approach to fight COVID-19

COVID-19 tissue atlases reveal SARS-1116

CoV-2 pathology and cellular targets

The spatial landscape of lung 1120 pathology during COVID-19 progression

Microtubule-dependent transport and dynamics of vimentin intermediate 1123 filaments

Intermediate filaments and 1125 vesicular membrane traffic: the odd couple's first dance?

Surface vimentin is critical for the cell entry of SARS-CoV

Vimentin binds to SARS-CoV-2 spike protein and antibodies targeting 1131 extracellular vimentin block in vitro uptake of SARS-CoV-2 virus-like particles. 1132 bioRxiv

A pneumonia outbreak associated with a new 1137 coronavirus of probable bat origin

Persistence of SARS CoV-2

S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19

Up to 15 Months Post-Infection. bioRxiv doi: 1143

The Lung Macrophage in 1145

Macrophages as Viral Targets and Reservoirs

Macrophages: a Trojan horse in COVID-19?

The lasting misery of coronavirus long-haulers

Deletion of Vimentin in Regulatory T 1153

Cells Augments Suppression Without Altering Homeostasis

A Distinct Function of Regulatory T Cells in Tissue 1157 Protection

Post-viral parenchymal lung disease of COVID-19 and viral 1160 pneumonitis: A systematic review and meta-analysis

ALD-R491 has no effect on other type III intermediate filaments. Left. No 1166 structural changes in GFAP in human glioma U87 cells treated with or without the 1167

including body weight and symptom. The animals that survived anesthesia were carried 764 to the experimental endpoint. As the mice were continuing to lose weight at all doses 765 and in both treatment arms and the disease scores were increasing, all animals were 766 euthanized at 5 days post-infection. Euthanasia was performed by inhalational 767 isoflurane (drop method) and thoracotomy, with removal of vital organs (lungs). Lung 768 tissue was taken for assessments of titer, RNA, and histology. Serum was taken for 769 downstream analysis. 770Histopathological examination of the lung: Lung specimens were fixed in 771 formalin and stained with hematoxylin and eosin for histological assessments. Lung 772 samples were scored by a board-certified veterinary pathologist for acute lung injury 773 (ALI) and diffuse alveolar damage (DAD). The ATS ALI score is a weighted composite 774 score based on the Matute-Bello rubric and considers neutrophils in the alveolar space, 775 neutrophils in the interstitium, hyaline membrane formation, protein in airspaces, and 776 alveolar septal thickening. All lung specimens were submitted for scoring; the 777 pathologist scored all specimens that were deemed suitable. Thus, at least 6 lungs were 778 scored in all conditions. 779 Statistical analyses were performed by Kruskal-Wallis test (Titer), One-way 780 ANOVA (Congestion score) or two tailed T Test (Weight loss, ATS ALI and DAD scores). The skin in the neck area was disinfected, then the skin layers were carefully incised to 797 have the trachea exposed. Bleomycin (BLM) was directly injected into left main 798 bronchus at a dose of 3mg/kg body weight in volume of 1.0 ml/kg via a cannula. After 799 the skin layers were closed, the animals were placed on an electric heat pad at 37 C 800 until they woke up from anesthesia before returning to holding cages with free access to 801 water and diet. 802 Experiment Groups and treatment regimen: The modeled rats were randomly 803 assigned into 5 groups (n=9 per group), treated p.o. via oral gavage respectively with 804 vehicle at 5 ml/kg/day, with BIBF1120 at 100 mg/kg/d prophylactically (q.d., from Day 1 805 to Day 21) or therapeutically (q.d., from Day 8 to Day 21), and with ALD-R491 at 100 806 mg/kg/d prophylactically (q.d., from Day 1 to Day 21) or therapeutically (q.d., from Day 8 807to Day 21). One day after the last dosing (Day 22), all animals were euthanized 808 37 according to the standard SOP at KCI Biotech. The animals were perfused systemically 809 with ice-cold saline, their left lungs were harvested and perfuse-fixed with 10% 810 formaldehyde solution (3ml of each lung), then processed for pathological analysis. 811Histopathological examination of the left lungs: The whole left lung was dehydrated 812 and embedded in paraffin wax. The sections were cut at a thickness of 4um and 813 processed for H&E and Masson's Trichrome staining. All the procedures were 814 performed according to KCI pathology SOPs. Whole slides were then scanned by 815Hamamatsu NanoZoomer Digital Pathology S210 slide scanner after staining. 816Bronchiole and pulmonary arteriole damage and inflammatory cell infiltration in 817 fibrosis core and fibrosis boarder areas were scored with H&E-stained slides. 818Criteria for grading the damage of terminal bronchiole wall were: score 0 for 819 normal structure; score 1 for normal structure with less than 1/2 of the terminal 820 bronchiole wall area injury and characterized by bronchial epithelial cells damage and 821 epithelium regeneration, wall edema, medium layer of the mucosal muscle degeneration 822 or regeneration; score 2 for structure with more than 1/2 of the terminal bronchiole wall 823 area injured and characterized by bronchial epithelial cells damage and epithelium 824 regeneration, wall edema, medium layer of the mucosal muscle degeneration or 825 regeneration; score 3 for structure with more than 1/2 area of the terminal bronchiole 826 wall injured and characterized by bronchial epithelial cells damage and epithelium 827 regeneration, wall edema, medium layer of the mucosal muscle degeneration or 828 regeneration, granulomas formation or fibrosis. 829Criteria for grading inflammatory cell infiltration in the terminal bronchiole wall 830were: score 0 for normal structure with no inflammatory cells infiltration; score 1 for a 831 38 few scattered but localized inflammatory cell infiltration (less than 10 cells per field) in 832 the outer wall of the terminal bronchiole; score 2 for numerous scattered inflammatory 833 cell infiltration that was focal or diffuse, affecting less than 1/2 of the total area of the 834 terminal bronchiole wall; .score 3 for diffuse infiltration of inflammatory cells that affected 835 more than 1/2 of the total area of the terminal bronchiole wall and extended to the inner 836 and the medium layers of basement membrane. 837Criteria for grading the damage of pulmonary small arteries wall were: score 0 for 838 the clear and complete structure of pulmonary small arteries; score 1 for partially 839 exfoliated endothelial cells; score 2 for exfoliated endothelial cells with degeneration, 840 regeneration or small focal necrosis in the medium layer of smooth muscle; score 3 for 841 exfoliated endothelial cells with degeneration, regeneration or small focal necrosis and 842 formation of granulomas or fibrosis. 843Criteria for grading inflammatory cell infiltration in the pulmonary arteriole were: 844 score 0 normal structure of pulmonary small arteries; score 1 for a few scattered and 845 localized inflammatory cell infiltration (less than 10 cells per field) in the outer wall of 846 pulmonary small arteries; score 2 for numerous scattered inflammatory cell infiltration, 847 affecting less than 1/2 of the total area of outer wall of pulmonary small arteries; score 3 848 for diffuse infiltration of inflammatory cells that affected more than 1/2 of the total area of 849 1/2 area of the pulmonary small artery wall and extended to the medium layer of the 850 basement membrane. 851

stained slides using Ashcroft scoring matrix. The criteria were: score 0 for the normal 853 structure with no fibrotic lesion in alveolar septum; score 1 for the isolated and simple 854 39 pulmonary fibrosis in alveolar septum (alveolar walls thicken but thinner than triple of 855 that for a normal lung), and little exudate and no fibrosis material in major alveolar areas; 856 score 2 for the clear fibrosis change in alveolar septum (alveolar walls thicker than triple 857 of that for a normal lung) with formation of small nodules that were not connected, and 858 little exudate and no fibrosis material in major alveolar areas; score 3 for the formation 859 early stage fibrosis forms in all alveoli in alveolar septum (alveolar walls thicker than 860 triple of that for a normal lung), and little exudate and no fibrosis material in major 861 alveolar areas; score 4 for the lung fibrosis with alveolar septum still visible, and the 862 formation of 863 isolated fibrosis nodules in alveolar areas (≤10% at high magnification); score 5 for the 864 lung fibrosis with alveolar septum still visible, the formation of integrated fibrosis nodule 865 in alveolar areas (>10% and ≤50% at high magnification), and the lung structure 866 substantially impaired but still existed; score 6 for the seen but barely alveolar septum 867 existed, and the formation of integrated fibrosis nodule in alveolar areas (>50% at high 868 magnification), and the lung structure barely existed; score 7 for the disappeared 869 alveolar septum, and the pulmonary alveoli and interstitial fibrosis proliferation seen but 870 still with vacuole structures; score 8 for the disappeared alveolar septum, and the 871 pulmonary alveoli and interstitial fibrosis proliferation seen at high magnification. Statistical analyses: Statistical analysis was performed using Graphpad prism 6.0 879 software. Descriptive results were expressed as mean ± sem or mean ± sd. Statistical 880 comparisons were performed using t-test, one-way analysis of variance or two-way 881 analysis of variance test. p<0.05 was considered as statistically significant. Histopathology was blindly evaluated by a board-certified pathologist. F. Lung tissues 1193 from all groups of mice were harvested on Day 5 and viral titers were measured by PCR. 1194 No statistical significance between infected vehicle group vs. individual treatment 1195 groups. 1196